ANAlison M. Newton

Alison M. Newton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alison M. Newton has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Piloting cannabis for sleep disturbance in palliative care over 5 weeks: The pillow study protocol

    by Alison M. Newton, Jessica L. Krok-Schoen, Erin E. Stevens, Shanna L. Babalonis, Theodore L. Wagener, Alice Hinton, Roberto Benzo, Theodore M. Brasky

    Background: Sleep disturbance affects 60% of cancer patients, 3-fold that of the general population, and is frequently driven by clinical characteristics, physical symptoms, and psychological distress. Sleep disturbance and other symptoms often exacerbate one another, leading to reduced health-related quality of life (HRQOL). Sleep is the most commonly reported reason for cannabis use among adults with cancer, yet clinical evidence supporting its use for symptom management remains limited. Objectives: This report describes a protocol for a pilot randomized trial designed to evaluate the safety and feasibility of a cannabis-based intervention and to explore its preliminary efficacy for sleep disturbance and HRQOL. Methods: This pilot parallel-arm randomized clinical trial will enroll 50 patients from the Ohio State University Comprehensive Cancer Center (OSUCCC; anticipated Fall 2026). Eligible participants will be new to the OSUCCC’s Palliative Care clinic and report at least moderate sleep disturbance. Participants will be randomized by sex and race strata to receive either usual care or a nightly oral cannabis gummy containing 5 mg Δ-9-tetrahydrocannabinol (THC) and 5 mg cannabidiol (CBD), taken 1 hour before bedtime for 30 days. Adverse events will be monitored throughout the study. Sleep, HRQOL, and related symptoms will be assessed using self-reported questionnaires, ecological momentary assessments, and actigraphy. Conclusions: Findings will provide critical safety, feasibility, and preliminary efficacy data to support a future large-scale, multisite trial targeting sleep disturbance and symptom palliation in cancer care.

  • Open Access

    Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.

  • Open Access

    Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.

  • Open Access

    Data from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background:Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence.Methods:We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk.Results:Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03).Conclusions:Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes.Impact:This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.

  • Open Access

    Supplementary Table 1 from Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Supplemental Table 1, shows associations of NSAIDs/aspirin with pancreatic cancer risk by categories of smoking, alcohol, and body mass index.

  • Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative

    by Theodore M. Brasky, Leah R. Jager, Alison M. Newton, Xilin Li, Holli A. Loomans-Kropp, John L. Hays, Karen L. Margolis, Juhua Luo

    Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.


  • Open Access

    Data from Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance:Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

  • Open Access

    Data from Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance:Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

  • Open Access

    Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance: Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.